269 related articles for article (PubMed ID: 6869857)
1. Activated coagulation and activated partial thromboplastin times in assessment and reversal of heparin-induced anticoagulation for cardiopulmonary bypass.
Dauchot PJ; Berzina-Moettus L; Rabinovitch A; Ankeney JL
Anesth Analg; 1983 Aug; 62(8):710-9. PubMed ID: 6869857
[TBL] [Abstract][Full Text] [Related]
2. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
[TBL] [Abstract][Full Text] [Related]
3. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
[TBL] [Abstract][Full Text] [Related]
4. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
[TBL] [Abstract][Full Text] [Related]
5. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
[TBL] [Abstract][Full Text] [Related]
6. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
[TBL] [Abstract][Full Text] [Related]
8. Aprotinin and heparin monitoring during cardiopulmonary bypass.
Hunt BJ; Segal H; Yacoub M
Circulation; 1992 Nov; 86(5 Suppl):II410-2. PubMed ID: 1385011
[TBL] [Abstract][Full Text] [Related]
9. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two protocols for heparin neutralization by protamine after cardiopulmonary bypass.
Arén C; Feddersen K; Rådegran K
J Thorac Cardiovasc Surg; 1987 Oct; 94(4):539-41. PubMed ID: 3309479
[TBL] [Abstract][Full Text] [Related]
11. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
12. [-Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty-].
Kunert M; Sorgenicht R; Scheuble L; Ketteler T; Lürken E; Meyer I; Müller A; Emmerich K; Gülker H
Z Kardiol; 1996 Feb; 85(2):118-24. PubMed ID: 8650981
[TBL] [Abstract][Full Text] [Related]
13. Activated clotting time tests with heparinase in the management of pediatric patients on cardiopulmonary bypass.
Kriesmer P; Payne NR; Tessmer J; Uden DL
ASAIO J; 1993; 39(4):942-5. PubMed ID: 8123932
[TBL] [Abstract][Full Text] [Related]
14. Activated coagulation time in monitoring heparinized dogs.
Green RA
Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
[TBL] [Abstract][Full Text] [Related]
16. [Heparin monitoring during cardiopulmonary bypass in congenital heart surgery].
Isomatsu Y; Imai Y; Seo K; Terada M; Aoki M; Shin'oka T
Kyobu Geka; 2000 Nov; 53(12):1001-4. PubMed ID: 11079303
[TBL] [Abstract][Full Text] [Related]
17. In vitro effect of fresh frozen plasma on the activated coagulation time in patients undergoing cardiopulmonary bypass.
Barnette RE; Shupak RC; Pontius J; Rao AK
Anesth Analg; 1988 Jan; 67(1):57-60. PubMed ID: 3257361
[TBL] [Abstract][Full Text] [Related]
18. [Control of temporary anticoagulation in extracorporeal circulation using activated coagulation time].
Kessler G; Grünes G
Anaesthesist; 1984 Dec; 33(12):588-91. PubMed ID: 6528961
[TBL] [Abstract][Full Text] [Related]
19. How much heparin do we really need to go on pump? A rethink of current practices.
Shuhaibar MN; Hargrove M; Millat MH; O'Donnell A; Aherne T
Eur J Cardiothorac Surg; 2004 Nov; 26(5):947-50. PubMed ID: 15519187
[TBL] [Abstract][Full Text] [Related]
20. Activated clotting time for control of anticoagulation during surgery.
Lefemine AA; Lewis M
Am Surg; 1985 May; 51(5):274-8. PubMed ID: 3994170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
